High-density lipoprotein metabolism as a therapeutic target for atherosclerosis

Michelle Albert, MD Elliott Antman, MD Donald S. Baim, MD Kenneth Baughman, MD Joshua Beckman, MD Gavin Blake, MD Charles M. Blatt, MD Eugene Braunwald, MD Christopher Cannon, MD Ming Hui Chen, MD Michael Chin, MD, PhD Mark Creager, MD Victor Dzau, MD Elazer Edelman, MD, PhD Andrew Eisenhauer, MD Laurence Epstein, MD James Fang, MD Mark Feinberg, MD Jonas Galper, MD, PhD Peter Ganz, MD J. Michael Gaziano, MD Marie Gerhard-Herman, MD Robert Giugliano, MD Michael Givertz, MD Samuel Z. Goldhaber, MD Thomas B. Graboys, MD Howard Hartley, MD Carolyn Ho, MD Mukesh Jain, MD John Jarcho, MD Paula Johnson, MD Ralph Kelly, MD Scott Kinlay, MD Jamil Kirdar, MD James Kirshenbaum, MD Gideon Koren, MD Richard Kuntz, MD Raymond Kwong, MD Michael J. Landzberg, MD Richard Lee, MD Eldrin Lewis, MD James Liao, MD Peter Libby, MD (Division Chief) Leonard Lilly, MD Bernard Lown, MD William Maisel, MD Thomas Michel, MD, PhD David Morrow, MD Karen Moulton, MD Gilbert Mudge, MD Anju Nohria, MD Patrick O’Gara, MD Marc A. Pfeffer, MD, PhD (Editor) Jorge Plutzky, MD Jeffrey Popma, MD Shmuel Ravid, MD Frederic Resnic, MD Paul Ridker, MD Thomas Rocco, MD Campbell Rogers, MD Maria Rupnick, MD, PhD Arthur Sasahara, MD S. Dinakar Satti, MD Jay Schneider, MD Christine Seidman, MD Andrew Selwyn, MD Daniel Simon, MD Laurence Sloss, MD Kyoko Soejima, MD Regina Sohn, MD Scott Solomon, MD Lynne Stevenson, MD William Stevenson, MD Peter Stone, MD Michael Sweeney, MD Frederick Welt, MD Justina Wu, MD

[1]  D. Rader,et al.  Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. , 2003, The Journal of clinical investigation.

[2]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[3]  D. Rader,et al.  Characterization of the lipolytic activity of endothelial lipase. , 2002, Journal of lipid research.

[4]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[5]  D. Rader,et al.  Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. , 2001, The American journal of cardiology.

[6]  M. Hayden,et al.  Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. , 2000, The Journal of clinical investigation.

[7]  M. Jaye,et al.  PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. , 2000, Nature medicine.

[8]  D. Rader,et al.  High-density lipoprotein metabolism: Molecular targets for new therapies for atherosclerosis , 2000, Current atherosclerosis reports.

[9]  A. Callow,et al.  Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[10]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[11]  Bezafibrate Infarction Prevention study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[12]  J. Mckenney,et al.  Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. , 2000, Archives of internal medicine.

[13]  D. Rader,et al.  Endothelial lipase colon; a new member of the triglyceride lipase gene family , 2000, Current opinion in lipidology.

[14]  D. Rader,et al.  Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. , 1999, Circulation.

[15]  D. Rader,et al.  ABC1: connecting yellow tonsils, neuropathy, and very low HDL. , 1999, The Journal of clinical investigation.

[16]  P. Barter,et al.  Remodelling of high density lipoproteins by plasma factors. , 1999, Atherosclerosis.

[17]  P. Connelly,et al.  The role of hepatic lipase in lipoprotein metabolism. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[18]  Sungshin Y. Choi,et al.  Cloning of a Unique Lipase from Endothelial Cells Extends the Lipase Gene Family* , 1999, The Journal of Biological Chemistry.

[19]  D. Rader,et al.  Role of fibrates in the management of hypertriglyceridemia. , 1999, The American journal of cardiology.

[20]  D. Rader,et al.  A novel endothelial-derived lipase that modulates HDL metabolism , 1999, Nature Genetics.

[21]  A. Goldberg,et al.  Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. , 1998, The American journal of cardiology.

[22]  D. Capuzzi,et al.  Treatment of hyperlipidemia with combined niacin-statin regimens. , 1998, The American journal of cardiology.

[23]  H. Suzuki,et al.  A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. , 1998, Preventive medicine.

[24]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[25]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[26]  G. Assmann,et al.  The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. , 1997, Journal of lipid research.

[27]  D. Rader,et al.  Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models , 1996, Current opinion in lipidology.

[28]  P. Barter,et al.  Molecular mechanisms of reverse cholesterol transport , 1996, Current opinion in lipidology.

[29]  S. Kihara,et al.  Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[30]  J. Ordovás,et al.  Familial hypoalphalipoproteinemia in premature coronary artery disease. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[31]  R. Krauss,et al.  Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. , 1993, The Journal of clinical investigation.

[32]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[33]  A. Tall Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. , 1990, The Journal of clinical investigation.

[34]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[35]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[36]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[37]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.